Name: Human Advanced Glycosylation End Products ELISA kit (E01A0002)
Brand: Shanghai BlueGene Biotech CO., LTD.
Price: 100 USD

BlueGene Biotech Human Advanced Glycosylation End Products ELISA kit (E01A0002)

E01A0002 Human Advanced Glycosylation End Products ELISA kit

Human Advanced Glycosylation End Products ELISA Kit is suitable for the detection of samples from the human species. Advanced Glycosylation End Products is also known as AGE, Glycotoxins, Advanced Glycosylation End Products, Non-enzymatic Glycosylation End Products, Diabetes Associated Advanced Glycation End Products (DAA), Maillard reaction products, Glycated proteins, Glycosylation products, Oxidative stress-derived AGEs, Reactive carbonyl species, Lipoxidation products.

Products

Specifications of Human Advanced Glycosylation End Products ELISA kit

Product Information
Cat. No.	E01A0002
Product Name	Human Advanced Glycosylation End Products ELISA Kit
Species	Human
Product Size	48 Tests / 96 Tests
Concentration	50-1000 pg/mL
Sensitivity	1.0 pg/mL
Principal	Sandwich ELISA
Sample Volume	50 ul
Sample Type	Serum, plasma, cell culture supernatants, body fluid and tissue homogenate
Assay Time	90 minutes
Platform	Microplate Reader
Conjugate	HRP
Detection Method	Colorimetric
Storage	2-8°C

Kit Components
MATERIALS	SPECIFICATION	QUANTITY
MICROTITER PLATE	96 wells	stripwell
ENZYME CONJUGATE	10 mL	1 vial
STANDARD A (0.5mL)	0 pg/mL	1 vial
STANDARD B (0.5mL)	50 pg/mL	1 vial
STANDARD C (0.5mL)	100 pg/mL	1 vial
STANDARD D (0.5mL)	250 pg/mL	1 vial
STANDARD E (0.5mL)	500 pg/mL	1 vial
STANDARD F (0.5mL)	1000 pg/mL	1 vial
SUBSTRATE A	6 mL	1 vial
SUBSTRATE B	6 mL	1 vial
STOP SOLUTION	6 mL	1 vial
WASH SOLUTION (100 x)	10 mL	1 vial
BALANCE SOLUTION	3 mL	1 vial

Principle of the Assay

AGES ELISA kit applies the quantitative sandwich enzyme immunoassay technique. The microtiter plate has been pre-coated with a monoclonal antibody specific for AGES. Standards or samples are then added to the microtiter plate wells and AGES if present, will bind to the antibody pre-coated wells. In order to quantitatively determine the amount of AGES present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody, specific for AGES are added to each well to “sandwich” the AGES immobilized on the plate. The microtiter plate undergoes incubation, and then the wells are thoroughly washed to remove all unbound components. Next, substrate solutions are added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain AGES and enzyme-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The AGES concentration in each sample is interpolated from this standard curve.

Quality Control on Human Advanced Glycosylation End Products ELISA kit

Coefficient of Variance	Intra Variation% ＜10%
	Inter Variation% ＜12%
Recovery	93-106%
Linearity	Diluent Ratio	Range %
	1:2	94-104
	1:4	90-109
	1:8	92-105
Specificity/Cross-reactivity	No significant cross-reactivity or interference between AGEs and analogues was observed.

BlueGene Biotech Product Show

Summary of the Assay Procedure for Human Advanced Glycosylation End Products ELISA kit

Citations of Human Advanced Glycosylation End Products ELISA kit

E01A0002 has been referenced in the below publications:

The correlation between aspirin resistance in patients with Diabetes and AGEs and HOMA-IR.

Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation endproducts in rhesus macaques with spontaneous hypertensive metabolic syndrome.

Ellagic acid reveals promising anti-aging effects against d-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: A mechanistic study.

Proximal Tubule Dysfunction Is Associated with Podocyte Damage Biomarkers Nephrin and Vascular Endothelial Growth Factor in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study.